The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) Study (SINGER)

August 23, 2021 updated by: Christopher Chen Li-Hsian, National University, Singapore

The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) Study, Biomarker and Health Service Research Analyses

A study in Finland found that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. A 6-month pilot study was initiated in Singapore, which demonstrated the cultural feasibility and practicality of the FINGER interventions and a set of locally adapted interventions in an Asian population. The SINGER study is a 2-year randomized controlled trial that aims to test the efficacy and safety of these lifestyle changes, including diet and cardiovascular risk factor management, cognitive and physical exercises, in delaying cognitive decline in older adults at risk of dementia.

Study Overview

Detailed Description

Results from a population-based 2-year clinical trial, the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), demonstrated that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. Currently, no pharmacological treatment options that can rival these effects. Thus, there is an urgent need to test the generalizability, adaptability, and sustainability of these findings in Singaporean populations. A 6-month pilot study was initiated in Singapore, which demonstrated the cultural feasibility and practicality of the FINGER interventions and a set of locally adapted interventions in an Asian population. Hence, the next step was to conduct a larger scale SINGER trial to determine the efficacy of these interventions in Singapore. If the interventions are found to be effective and safe with high applicability and scalability, the study will provide important clinical and public health implications to a rapidly increasing ageing population.

Study Type

Interventional

Enrollment (Anticipated)

1200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Singapore, Singapore, 117600
        • Recruiting
        • National University Hospital
        • Contact:
        • Principal Investigator:
          • Christopher LH Chen, MD
        • Sub-Investigator:
          • Effie Chew, MD
        • Sub-Investigator:
          • Chester Drum, MD, PhD
        • Sub-Investigator:
          • Dave YH Lee, MD
        • Sub-Investigator:
          • Mingchang Wang, MD
      • Singapore, Singapore, 117600
        • Recruiting
        • National University of Singapore, Yong Loo Lin School of Medicine
        • Contact:
        • Principal Investigator:
          • Christopher LH Chen, MD
        • Sub-Investigator:
          • Christiani J Henry, PhD
        • Sub-Investigator:
          • Josip Car, MD, PhD
        • Sub-Investigator:
          • Juan H Zhou, PhD
        • Sub-Investigator:
          • Mark Richards, MD, PhD, Dsc
        • Sub-Investigator:
          • Mitchell Lai, PhD
        • Sub-Investigator:
          • Jianjun Liu, PhD
      • Singapore, Singapore, 308433
        • Not yet recruiting
        • National Neuroscience Institute @ Tan Tock Seng Campus (NNI @ TTSH campus)
        • Contact:
        • Contact:
        • Principal Investigator:
          • Nagaendran Kandiah, MD
        • Sub-Investigator:
          • John Chambers, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 77 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 60-77 years
  • Able to understand English/Chinese
  • Risk of dementia: Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) dementia risk score >6 indicating the presence of modifiable risk factors Modifiable lifestyle factors (fulfilling at least one of the following LIBRA index for diet, cognitive activity, physical activity)
  • Cognitive performance at the mean level or slightly lower than expected for age (MoCA ≥18, ≤27)
  • No plans to travel outside of Singapore for an extended period of time over the course of the study
  • Free of physical disabilities that preclude participation in the study
  • Willing to complete all study-related activities for 24 months
  • Willing to be randomized to either lifestyle intervention group

Exclusion Criteria:

  • malignant diseases
  • dementia
  • substantial cognitive decline (MoCA<18)
  • major depression
  • symptomatic cardiovascular disease
  • revascularisation within 1 year
  • severe loss of vision, hearing or communicative ability
  • other conditions inhibiting from safe engagement in the prescribed intervention and other conditions preventing cooperation, as judged by the study physician

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Structured Lifestyle Intervention
Structured lifestyle modification program developed for participants targeting diet, physical exercise, cognitive training, and social stimulation.
Structured Lifestyle Intervention (SLI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.
Other Names:
  • SLI
Experimental: Self-Guided Intervention
General health information provided to participants.
In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.
Other Names:
  • SGI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global Cognition
Time Frame: Up to 2 years
Global cognition measured using the modified Neuropsychological Test Battery (mNTB) that includes: Visual Paired Associates, Logical Memory Recall of the Wechsler Memory Scale-Revised, Rey Auditory Verbal Learning, Digit Span, Word and Category Fluency test, Trail Making Test, Letter Digit Substitution test.
Up to 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Episodic Memory
Time Frame: Up to 2 years
Episodic memory measured using mNTB subtests: Visual paired associates tests, Logical Memory immediate and delayed recall of the Wechsler Memory Scale-Revised, Rey Auditory Verbal Learning test.
Up to 2 years
Executive Function
Time Frame: Up to 2 years
Executive function measured using mNTB subtests: Digit Span, Word and Category Fluency test, Trail Making Test Part B.
Up to 2 years
Processing Speed
Time Frame: Up to 2 years
Processing speed measured using mNTB subtests: Letter Digit Substitution test and Trail-Making Test Part A.
Up to 2 years
Clinical Dementia Rating-Sum of Boxes (CDR-SB)
Time Frame: Up to 2 years
The Clinical Dementia Rating-Sum of Boxes (CDR-SB) is scored from 0 to 18. Higher scores reflect worse performance.
Up to 2 years
Alzheimer's Disease Cooperative Study Activities of Daily Living-Mild Cognitive Impairment-Activities of Daily Living Inventory (ADCS-MCI-ADL)
Time Frame: Up to 2 years
The Alzheimer's Disease Cooperative Study Activities of Daily Living-Mild Cognitive Impairment-Activities of Daily Living Inventory (ADCS-MCI-ADL) is scored from 0 to 53. Higher scores reflect better performance.
Up to 2 years
The Geriatric Depression Scale (GDS)
Time Frame: Up to 2 years
The Geriatric Depression Scale (GDS) is scored from 0 to 15. Scores of 0-4 are considered normal, 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.
Up to 2 years
Global Physical Activity Questionnaire (GPAQ)
Time Frame: Up to 2 years
The Global Physical Activity Questionnaire (GPAQ) measures physical activity across 3 domains: work, travel, and recreation, as well as average time per day spent in sedentary behavior. The GPAQ is scored based on a population's mean or median physical activity spent in physical activity or by classifying a certain percentage of a population as 'inactive' or 'insufficiently active'.
Up to 2 years
Prospective-Retrospective Memory Questionnaire
Time Frame: Up to 2 years
The Prospective-Retrospective Memory Questionnaire (PRMQ) is measured on a 5-point scale. Higher scores represent greater frequency of memory failures.
Up to 2 years
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Up to 2 years
The Pittsburgh Sleep Quality Index (PSQI) is scored from 0 to 21. Higher scores indicate worse sleep quality.
Up to 2 years
Leisure-Time Activities Questionnaire
Time Frame: Up to 2 years
The Leisure-Time Activities Questionnaire measures the frequency of engagement in the following activities: Health activities, Social activities, Productive activities, Fitness activities, Recreational activities, Any cognitively-stimulating activities. Scores are measured on a 3-point scale. Higher scores represent higher frequency of engagement in leisure-time activities.
Up to 2 years
Physical Performance Test (PPT)
Time Frame: Up to 2 years
The Physical Performance Test (PPT) is scored from 0 to 36. Higher scores represent better performance.
Up to 2 years
Quality of Life Questionnaire (15D)
Time Frame: Up to 2 years
The Quality of Life Questionnaire (15D) has a single index (15D score) on a 0-1 scale, which represents overall HRQoL (0 = being dead, 0.0162 = being unconscious or comatose, 1 = no problems on any dimension = 'full' HRQOL). This is calculated from the health state descriptive system by using a set of population-based preference or utility weights.
Up to 2 years
36-Item Short Form Survey (SF-36)
Time Frame: Up to 2 years
The 36-Item Short Form Survey (SF-36) has eight domains. Each domain is scored from 0 to 100. Higher scores represent a more favourable health state.
Up to 2 years
Resource Use Inventory (RUI)
Time Frame: Up to 2 years
The Resource Use Inventory (RUI) measures 4 domains: direct medical care, direct nonmedical care, informal care, and subjects' time use. The RUI is filled in based on the frequency and amount of resources used. If none were used, '00' is entered.
Up to 2 years
Height
Time Frame: Up to 2 years
Height is measured in metres.
Up to 2 years
Weight
Time Frame: Up to 2 years
Weight is measured in kilograms.
Up to 2 years
Hip and waist circumference
Time Frame: Up to 2 years
Hip and waist circumference measured in centimetres.
Up to 2 years
Changes in Blood Pressure
Time Frame: Up to 2 years
Vascular and metabolic risk factors measured by changes in blood pressure in mmHg. Incident events using serious adverse event reports will also be assessed.
Up to 2 years
Changes in Lipid Profile
Time Frame: Up to 2 years
Vascular and metabolic risk factors measured by changes in lipid profile in mmol/L.
Up to 2 years
Changes in Glucose Regulation
Time Frame: Up to 2 years
Vascular and metabolic risk factors measured by changes in glucose regulation in mmol/L.
Up to 2 years
Neuroimaging
Time Frame: Up to 2 years
Magnetic Resonance Imaging will be used to assess changes in brain structural integrity, grey matter volume loss, white matter microstructure degradation, and increase of cerebrovascular disease markers (CeVD). Vascular polygenic risk scores (PRS) and its association with neurodegeneration, CeVD burden and cognitive decline will be performed.
Up to 2 years
Blood Biomarkers
Time Frame: Up to 2 years
Novel and accessible blood markers to monitor AD- and CeVD-associated pathologies will be measured. Plasma concentrations of cardiac markers (High-sensitive cardiac troponin T (hs Troponin T), N-terminal pro b-type natriuretic peptide (NT-proBNP) and Growth/differentiation factor 15 (GDF 15)), and peripheral biomarkers of Aβ, tau and synaptic pathology, oxidative stress, endothelial/cardiovascular injury and degenerative protein modifications (DPMs) damaged proteins will be used.
Up to 2 years
Retinal Imaging Markers
Time Frame: Baseline only
Multimodal retinal imaging will be used to assess retinal structural, vascular and neuronal changes.
Baseline only

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christopher LH Chen, MD, National University, Singapore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 23, 2021

Primary Completion (Anticipated)

December 31, 2025

Study Completion (Anticipated)

January 31, 2026

Study Registration Dates

First Submitted

July 28, 2021

First Submitted That Met QC Criteria

August 10, 2021

First Posted (Actual)

August 16, 2021

Study Record Updates

Last Update Posted (Actual)

August 24, 2021

Last Update Submitted That Met QC Criteria

August 23, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

Interested collaborators may put in a request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mental Disorders

Clinical Trials on Structured Lifestyle Intervention

Subscribe